| # | Title | Journal | Year | Citations |
|---|
| 1 | EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations | Leukemia | 2012 | 409 |
| 2 | Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia---results of the prospective multicenter LALA-94 trial | Blood | 2002 | 344 |
| 3 | Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study | Blood | 2007 | 300 |
| 4 | Molecular International Prognostic Scoring System for Myelodysplastic Syndromes | | 2022 | 259 |
| 5 | Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma | New England Journal of Medicine | 1993 | 248 |
| 6 | Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation | Bone Marrow Transplantation | 1998 | 240 |
| 7 | Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study | Blood | 1999 | 238 |
| 8 | Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time | Bone Marrow Transplantation | 2005 | 232 |
| 9 | Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation | Blood | 2010 | 227 |
| 10 | Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe | Bone Marrow Transplantation | 2006 | 192 |
| 11 | Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup | Blood | 2003 | 175 |
| 12 | A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup | Blood | 2002 | 170 |
| 13 | Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial | Blood | 2007 | 160 |
| 14 | Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia | Journal of Clinical Oncology | 2003 | 146 |
| 15 | Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group | Leukemia | 2005 | 134 |
| 16 | Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation | Blood | 2000 | 134 |
| 17 | Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia | Leukemia | 2011 | 120 |
| 18 | L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature | Annals of Oncology | 2009 | 111 |
| 19 | Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study | Leukemia | 2006 | 106 |
| 20 | A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia | Nature Medicine | 2022 | 104 |
| 21 | Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation | Leukemia | 2000 | 94 |
| 22 | Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults | HemaSphere | 2018 | 91 |
| 23 | The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication | Blood | 2009 | 87 |
| 24 | Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia | Leukemia | 2016 | 86 |
| 25 | Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry | British Journal of Haematology | 2022 | 85 |
| 26 | Differences between graft product and donor side effects following bone marrow or stem cell donation | Bone Marrow Transplantation | 2003 | 76 |
| 27 | Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group | Leukemia | 2007 | 74 |
| 28 | The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation | Blood | 2011 | 73 |
| 29 | Comparison among acquired immune deficiency syndrome patients with and without clinical evidence of cardiac disease | American Journal of Cardiology | 1988 | 66 |
| 30 | A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society | Bone Marrow Transplantation | 2003 | 61 |
| 31 | Hematological malignancy associated with polymyositis and dermatomyositis | Autoimmunity Reviews | 2012 | 61 |
| 32 | Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors | Bone Marrow Transplantation | 2006 | 59 |
| 33 | Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia | Blood | 2018 | 54 |
| 34 | Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial | Leukemia and Lymphoma | 2012 | 50 |
| 35 | Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia | Cancer | 2020 | 49 |
| 36 | New Treatment Options for Acute Myeloid Leukemia in 2019 | Current Oncology Reports | 2019 | 49 |
| 37 | Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA | Blood | 2021 | 48 |
| 38 | Hypomethylating Agents as a Therapy for AML | Current Hematologic Malignancy Reports | 2017 | 47 |
| 39 | In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy | Leukemia | 1995 | 45 |
| 40 | Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study | Bone Marrow Transplantation | 2000 | 43 |
| 41 | Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) | Journal of Hematology and Oncology | 2017 | 43 |
| 42 | Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials | Leukemia | 2006 | 42 |
| 43 | Pediatric-Like Therapy for Adults with ALL | Current Hematologic Malignancy Reports | 2014 | 40 |
| 44 | Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) | American Journal of Hematology | 2021 | 40 |
| 45 | Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel | Critical Reviews in Oncology/Hematology | 2017 | 38 |
| 46 | Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study | Blood | 2021 | 36 |
| 47 | Prognosis of patients with advanced hodgkin's disease | | 1997 | 35 |
| 48 | Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia | Leukemia and Lymphoma | 2016 | 35 |
| 49 | Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association | Biology of Blood and Marrow Transplantation | 2016 | 35 |
| 50 | Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia | Leukemia | 1997 | 34 |
